Graft versus host disease (GvHD) occurs in half the patients who receive allogenic
haematopoietic stem cell transplantation and is a major contributor for the morbidity and …

Graft-versus-host disease (GVHD)* is a frequent complication of allogeneic bone marrow
transplantation. The potentially beneficial effect of phototherapy for treatment of cutaneous …

Skin is usually the first and most affected organ involved in graft‐versus‐host disease
(GvHD), and treatment is still a clinical challenge. Although the need for skin‐directed …

Introduction and objectives Cutaneous chronic graft-vs-host disease (GVHD) is a common
complication of hematopoietic stem cell transplantation. Phototherapy is a therapeutic option …

Background: Chronic cutaneous graft-versus-host disease (GvHD) can arise as a late
complication after allogeneic bone marrow transplantation. Patients with extensive disease …

Background: Cutaneous chronic graft versus host disease (GVHD) is a severe complication
following allogeneic stem cell (PBSCT) and bone marrow transplantation (BMT) …

Long-wavelength ultraviolet A (340–400 nm UVA1) phototherapy has been reported to be
effective in atopic dermatitis, localized scleroderma and other T-cell-derived skin diseases …

Graft-vs-host disease (GVHD) remains a major cause of morbidity and mortality after
allogeneic stem cell transplantation. GVHD was first described by Barnes and Mole1 as a …

Background Up to 50% of patients undergoing allogenic stem cell transplantation or bone
marrow transplantation (BMT) can develop acute or chronic graft versus host disease …

BACKGROUND AND OBJECTIVES: Standard or investigative immunosuppressive
therapies for cutaneous chronic graft-versus-host disease (GVHD) may prove not only …